DOP062 The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy
Geert D’Haens(Amsterdam University Medical Centers), William J. Sandborn(University of San Diego), Fabio Cataldi(Pfizer (United States)), Y Wang(Takeda (United States)), Ken Gorelick(Pfizer (United States))
Cited by 2
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
|Clinical Gastroenterology and Hepatology|2006|906
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
|Gastroenterology|1998|865